Literature DB >> 27715398

Survivin is a guardian of the intestinal stem cell niche and its expression is regulated by TGF-β.

Eva Martini1, Evelyn Schneider1, Clemens Neufert1, Markus F Neurath1, Christoph Becker1.   

Abstract

As an inhibitor of apoptosis (IAP) family member, Survivin is known for its role during regulation of apoptosis. More recently its function as a cell cycle regulator has become evident. Survivin was shown to play a pivotal role during embryonic development and is highly expressed in regenerative tissue as well as in many cancer types. We examined the function of Survivin during mouse intestinal organogenesis and in gut pathophysiology. We found high expression of Survivin in experimentally induced colon cancer in mice but also in colon tumors of humans. Moreover, Survivin was regulated by TGF-β and was found to be highly expressed during mucosal healing following intestinal inflammation. We identified that expression of Survivin is essential early on in life, as specific deletion of Survivin in Villin expressing cells led to embryonic death around day 12 post coitum. Together with our recent study on the role of Survivin in the gut of adult mice our data demonstrate that Survivin is an essential guardian of embryonic gut development and adult gut homeostasis protecting the epithelium from cell death promoting the proliferation of intestinal stem and progenitor cells.

Entities:  

Keywords:  BIRC5; colorectal cancer; inflammation; intestinal epithelium; mitotic catastrophe

Mesh:

Substances:

Year:  2016        PMID: 27715398      PMCID: PMC5105921          DOI: 10.1080/15384101.2016.1231286

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  27 in total

1.  Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma.

Authors:  Chao-Ping Ye; Cheng-Zhi Qiu; Zhong-Xin Huang; Qi-Chen Su; Wei Zhuang; Rui-Lan Wu; Xin-Feng Li
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

Review 2.  Transcriptional regulation of the survivin gene.

Authors:  Romain Boidot; Frédérique Végran; Sarab Lizard-Nacol
Journal:  Mol Biol Rep       Date:  2013-11-07       Impact factor: 2.316

3.  IL-6 signaling promotes tumor growth in colorectal cancer.

Authors:  C Becker; M C Fantini; S Wirtz; A Nikolaev; H A Lehr; P R Galle; S Rose-John; M F Neurath
Journal:  Cell Cycle       Date:  2005-02-03       Impact factor: 4.534

Review 4.  Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events.

Authors:  Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2007-01-09       Impact factor: 4.534

5.  In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy.

Authors:  C Becker; M C Fantini; S Wirtz; A Nikolaev; R Kiesslich; H A Lehr; P R Galle; M F Neurath
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

6.  Expression and significance of survivin in colorectal high grade and low grade adenomas.

Authors:  Marian Adamkov; Desanka Výbohová; Veronika Tupá; Jaroslava Chylíková; Jaroslav Horáček; Marián Benčat
Journal:  Acta Histochem       Date:  2015-06-18       Impact factor: 2.479

7.  Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.

Authors:  Donal J Brennan; Elton Rexhepaj; Sallyann L O'Brien; Elaine McSherry; Darran P O'Connor; Ailís Fagan; Aedín C Culhane; Desmond G Higgins; Karin Jirstrom; Robert C Millikan; Goran Landberg; Michael J Duffy; Stephen M Hewitt; William M Gallagher
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

8.  Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications.

Authors:  S Mohamed; K Yasufuku; T Nakajima; K Hiroshima; M Chiyo; S Yoshida; M Suzuki; Y Sekine; K Shibuya; G Agamy; H El-Shahhat; T Fujisawa; I Yoshino
Journal:  Eur Respir J       Date:  2008-08-20       Impact factor: 16.671

9.  The role of γ-tubulin in centrosomal microtubule organization.

Authors:  Eileen O'Toole; Garrett Greenan; Karen I Lange; Martin Srayko; Thomas Müller-Reichert
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

10.  Suppressed diversity of survivin splicing in active rheumatoid arthritis.

Authors:  Minna Turkkila; Karin M E Andersson; Sylvie Amu; Mikael Brisslert; Malin C Erlandsson; Sofia Silfverswärd; Maria I Bokarewa
Journal:  Arthritis Res Ther       Date:  2015-07-10       Impact factor: 5.156

View more
  11 in total

Review 1.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Authors:  Fengzhi Li; Tao Jiang; Qingyong Li; Xiang Ling
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

Review 2.  Survivin at a glance.

Authors:  Sally P Wheatley; Dario C Altieri
Journal:  J Cell Sci       Date:  2019-04-04       Impact factor: 5.285

3.  Epithelial TNF Receptor Signaling Promotes Mucosal Repair in Inflammatory Bowel Disease.

Authors:  Emily M Bradford; Stacy H Ryu; Ajay Pal Singh; Goo Lee; Tatiana Goretsky; Preetika Sinh; David B Williams; Amber L Cloud; Elias Gounaris; Vihang Patel; Olivia F Lamping; Evan B Lynch; Mary Pat Moyer; Isabelle G De Plaen; David J Shealy; Guang-Yu Yang; Terrence A Barrett
Journal:  J Immunol       Date:  2017-07-26       Impact factor: 5.422

Review 4.  Differential Impacts of Alternative Splicing Networks on Apoptosis.

Authors:  Jung-Chun Lin; Mei-Fen Tsao; Ying-Ju Lin
Journal:  Int J Mol Sci       Date:  2016-12-14       Impact factor: 5.923

Review 5.  Cytokine Tuning of Intestinal Epithelial Function.

Authors:  Caroline Andrews; Mairi H McLean; Scott K Durum
Journal:  Front Immunol       Date:  2018-06-05       Impact factor: 7.561

6.  Large-scale analyses identify a cluster of novel long noncoding RNAs as potential competitive endogenous RNAs in progression of hepatocellular carcinoma.

Authors:  Mengjia Song; Ailin Zhong; Jieying Yang; Junyi He; Shaoyan Cheng; Jianxiong Zeng; Yue Huang; Qiuzhong Pan; Jingjing Zhao; Ziqi Zhou; Qian Zhu; Yan Tang; Hao Chen; Chaopin Yang; Yuan Liu; Xiaocong Mo; Desheng Weng; Jian-Chuan Xia
Journal:  Aging (Albany NY)       Date:  2019-11-23       Impact factor: 5.682

7.  Insight into Cisplatin-Resistance Signaling of W1 Ovarian Cancer Cells Emerges mTOR and HSP27 as Targets for Sensitization Strategies.

Authors:  Kathleen Wantoch von Rekowski; Philipp König; Svenja Henze; Martin Schlesinger; Piotr Zawierucha; Radosław Januchowski; Gerd Bendas
Journal:  Int J Mol Sci       Date:  2020-12-03       Impact factor: 5.923

8.  Investigation of Colonic Regeneration via Precise Damage Application Using Femtosecond Laser-Based Nanosurgery.

Authors:  Sören Donath; Leon Angerstein; Lara Gentemann; Dominik Müller; Anna E Seidler; Christian Jesinghaus; André Bleich; Alexander Heisterkamp; Manuela Buettner; Stefan Kalies
Journal:  Cells       Date:  2022-03-28       Impact factor: 6.600

9.  An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer.

Authors:  Xiang Ling; Wenjie Wu; Chuandong Fan; Chao Xu; Jianqun Liao; Laurie J Rich; Ruea-Yea Huang; Elizabeth A Repasky; Xinjiang Wang; Fengzhi Li
Journal:  J Exp Clin Cancer Res       Date:  2018-10-03

Review 10.  Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity.

Authors:  Shannon Lee; Jens Rauch; Walter Kolch
Journal:  Int J Mol Sci       Date:  2020-02-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.